Merck & Company Inc (MRK)vsTilray Inc (TLRY)
MRK
Merck & Company Inc
$146.35
+3.83%
HEALTHCARE · Cap: $360.08B
TLRY
Tilray Inc
$2.69
-2.89%
HEALTHCARE · Cap: $409.37M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 6812% more annual revenue ($66.57B vs $963.10M). MRK leads profitability with a 4.8% profit margin vs -17.1%. TLRY earns a higher WallStSmart Score of 40/100 (D).
MRK
Hold36
out of 100
Grade: F
TLRY
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$146.35
$62.71 premium
Intrinsic value data unavailable for TLRY.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 22.7% year-over-year
Areas to Watch
Trading at 8.6x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -10.1% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : TLRY
The strongest argument for TLRY centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 22.7% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : TLRY
The primary concerns for TLRY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while TLRY is a growth play — different risk/reward profiles.
TLRY carries more volatility with a beta of 1.92 — expect wider price swings.
TLRY is growing revenue faster at 22.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
TLRY scores higher overall (40/100 vs 36/100) and 22.7% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Tilray Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Tilray Inc. is dedicated to the research, cultivation, production and distribution of medicinal cannabis and cannabinoids. The company is headquartered in Leamington, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?